The benefits of antiepileptic drug (AED) blood level monitoring to complement clinical management of people with epilepsy

Epilepsy and Behavior

Volumn 42, Issue , 2015, Pages 7-9

  Stepanova, Daria ^a   Beran, Roy G ^a,b,c  

^a Strategic Health Evaluators   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

AED blood levels; AED interactions; AED toxicity; Compliance; Generic substitution

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; ETIRACETAM; GENERIC DRUG; LAMOTRIGINE; PHENYTOIN; VALPROIC ACID;

ARTICLE; CLUSTER SEIZURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG INDUSTRY; DRUG MONITORING; EPILEPSY; EPILEPTIC STATE; HUMAN; MEDICATION COMPLIANCE; PATIENT CARE; PATIENT COMPLIANCE; POLYPHARMACY; SEIZURE; BLOOD; CASE MANAGEMENT; COMPLICATION; PROCEDURES; SEIZURES; THERAPEUTIC EQUIVALENCE;

ANTICONVULSANTS; CASE MANAGEMENT; DRUG MONITORING; DRUGS, GENERIC; EPILEPSY; HUMANS; PATIENT COMPLIANCE; POLYPHARMACY; SEIZURES; STATUS EPILEPTICUS; THERAPEUTIC EQUIVALENCY;

EID: 84916593636     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2014.09.069     Document Type: Article

References (37)

1. Vajda F.J.E. Monitoring anti-epileptic drug therapy with serum level measurements. Med J Aust 2007, 187:581.
2. Conway J.M., Henry T.R. Anti-epilepsy drugs: mechanisms of action and pharmacokinetics. Epilepsy board review manual 2012, 1:1-11.
3. Beran R.G. The use of drug levels to treat cluster seizures in epilepsy management. J Neurol Neurophysiol 2011, S2:1-2.
4. Carpentier N., Jonas J., Frismand S., Vignal J.P., Rikir E., Baumann C., et al. Direct evidence of non-adherence to anti-epileptic medication in refractory focal epilepsy. Epilepsia 2013, 54:e20-e23.
5. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants?. Clin Pharmacokinet 2000, 38:191-204.
6. Huff J.S., Melnick E.R., Tomaszewski C.A., Thiessen M.E., Jagoda A.S., Fesmire F.M., et al. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with seizures. Ann Emerg Med 2014, 63:437-447.
7. Cloyd J.C., Lalonde R.L., Beniak T.E., Novack G.D. A single-blind, crossover comparison of the pharmacokinetics and cognitive effects of a new diazepam rectal gel with intravenous diazepam. Epilepsia 1998, 39:520-526.
8. Patel V., Cordato D.J., Malkan A., Beran R.G. Rectal carbamazepine as effective long-acting treatment after cluster seizures and status epilepticus. Epilepsy Behav 2014, 31:31-33.
9. Beran R.G. An alternative perspective to the management of status epilepticus. Epilepsy Behav 2008, 12:349-353.
10. Höfler J., Unterberger I., Dobesberger J., Kuchukhidze G., Walser G., Trinka E. Intravenous lacosamide in status epilepticus and cluster seizures. Epilepsia 2011, 52:e148-e152.
11. Roman-Filip C., Gligor F., Ungureanu A., Prodan L. Intravenous valproic acid for the treatment of status epilepticus and seizure clusters. Farmacia 2013, 61:742-747.
12. Pellock J.M. Management of acute seizure episodes. Epilepsia 1998, 39:S28-S35.
13. Duncan J.S., Shorvon S.D., Fish D.R. Clinical epilepsy 1995, Churchill Livingstone, New York.
14. Nair P.P., Kalita J., Misra U.K. Status epilepticus: why, what and how. J Postgrad Med 2011, 57:242-252.
15. Mirò J., Toledo M., Santamarina E., Ricciardi A.C., Villanueva V., Pato A., et al. Efficacy of intravenous lacosamide as an add-on treatment in refractory status epilepticus: a multicentric prospective study. Seizure 2013, 22:77-79.
16. Cohan S.L. Antiepileptic therapeutic drug monitoring. Clin Lab Med 1981, 1:479-500.
17. French J.A., Faught E. Rational polytherapy. Epilepsia 2009, 50:63-68.
18. Brodie M.J., Dichter M.A. Antiepileptic drugs. N Engl J Med 1996, 334:168-175.
19. Kee V.R., Gilchrist B., Granner M.A., Sarrazin N.R., Carnahan R.M. A systematic review of validated methods for identifying seizures, convulsions, or epilepsy using administrative and claims data. Pharmacoepidemiol Drug Saf 2012, 21:183-193.
20. Swaroop H.S., Ananya C., Nithin K., Jayashankar C.A., Satish Babu H.V., Srinivas B.N. Levetiracetam: a review of its use in the treatment in epilepsy. Int J Med Biomed Res 2013, 2:166-172.
21. Za'abi M.A., Asmi A.A., Ahmed R., Al-Masrouri S., Al-Lawati R., Nandhagopal R., et al. Therapeutic antiepileptic drug monitoring pattern in a tertiary care hospital in Oman. Afr J Pharm Pharmacol 2013, 7:58-62.
22. Stepanova D., Beran R.G. Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs). Seizure 2014, 23:371-376.
23. Beran R.G., Berkovic S.F., Black A.B., Danta G., Hiersemenzel R., Schapel G.J., et al. Efficacy and safety of levetiracetam 1000-3000mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study. Epilepsy Res 2005, 63:1-9.
24. Privitera M. Efficacy of levetiracetam: a review of three pivotal clinical trials. Epilepsia 2001, 42:31-35.
25. Korby B., Penovich P.E., Gates J.R., Dickens D.L., Moriarty G.L. Levetiracetam monotherapy. Epilepsia 2003, 44:108-114.
26. Lasoń W., Dudra-Jastrze'bska M., Rejdak K., Czuczwar S.J. Basic mechanisms of antiepileptic drugs and their pharmacokinetic/pharmacodynamic interactions: an update. Pharmacol Rep 2011, 63:271-292.
27. Tomson T., Landmark C.J., Battino D. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia 2013, 54:405-414.
28. Chan K., Beran R.G. Value of therapeutic drug level monitoring and unbound (free) levels. Seizure 2008, 17:572-575.
29. Crawford P., Feely M., Guberman A., Kramer G. Are there potential problems with generic substitution of anti-epileptic drugs? A review of issues. Seizure 2006, 15:165-176.
30. Bialer M., Midha K.K. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability. Epilepsia 2010, 51:941-950.
31. Gidal B.E., Tomson T. Debate: substitution of generic drugs in epilepsy: is there cause for concern?. Epilepsia 2008, 49:56-62.
32. Maliepaard M., Banishki N., Gispen-de Wied C.C., Teerenstra S., Elferink A.J. Interchangeability of generic anti-epileptic drugs: a quantitative analysis of topiramate and gabapentin. Eur J Clin Pharmacol 2011, 67:1007-1016.
33. Bialer M. Generic products of antiepileptic drugs (AEDs): is it an issue?. Epilepsia 2007, 48:1825-1832.
34. Patel V., Cordato D.J., Dias M., Beran R.G. Changed constitution without change in brand name - the risk of generics in epilepsy. Epilepsy Res 2012, 98:269-272.
35. Camfield P., Camfield C. Monitoring for adverse effects of anti-epileptic drugs. Epilepsia 2006, 47(Suppl 1):31-34.
36. Smyrna G.A. Data on file 2001, UCB Pharma Inc.
37. Eatock J., Baker G.A. Managing patient adherence and quality of life in epilepsy. Neuropsychiatr Dis Treat 2007, 3:117-131.